Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab Plus Anlotinib in Recurrent Sporadic MMRd Endometrial Cancer
NCT05550558Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Nov 2022
- Primary completion
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
01
Overview
A Phase 2 trial of anlotinib, camrelizumab in endometrial cancer (EC), sponsored by Sun Yat-sen Memorial Hospital. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
anlotinibcamrelizumab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT05550558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05550558.